It may be difficult for an ophthalmologist to decide upon the best course of management for a patient with uveal melanoma, especially in view of the rarity and the lethal nature of the disease and because of the complexity of various forms of treatment. The aim of this article is to provide a guide to the selection of treatment for intra ocular melanoma and it is directed at the general ophthal mologist who is likely to encounter the problem only occasionally. The published literature is still incomplete so that subjective opinions cannot be avoided where statis tical comparative data are not available.
INDICATIONS FOR TREATMENT
There is no doubt about the fundamental need to destroy the primary tumour completely before lethal extraocular dissemination has occurred. At present, however, the effi cacy of treatment in preventing metastatic death remains uncertain. This situation exists firstly because metastases can be detected only at a late stage, when death is immi nent, and secondly because the shortest possible latent period between the time of tumour seeding and the onset of clinical metastatic disease is not known. Workers such as Zimmerman, who believe that this latent period can be as short as 1 year, have suggested that treatment can accel erate metastatic death.! An opposing view, held by workers such as Manschot, is that the minimum latent period is about 7 years, so that any metastatic deaths occurring less than 7 years after treatment are the result of tumour dissemination before treatment.2 Pre-enucleation radiotherapy and various modifications of enucleation aimed at reducing tumour seeding do not seem to have reduced the risk of metastatic disease,3-7 but it is perhaps too soon to draw valid conclusions from such studies. Improved methods of detecting tumour cells in the general circulation8 may provide insights into the process of meta static disease. In the meantime, as long as it remains impossible to establish whether or not a patient is already doomed because of sub-clinical micrometastases, all patients with a definitive diagnosis of uveal melanoma Eye (1993) 7, 388-397 who are not obviously moribund must be treated without undue delay, especially in view of the incurable and letha1 nature of metastatic disease.
It must be remembered that there are other reasons for treating uveal melanomas, apart from the prevention of metastatic disease. The tumour is likely to cause visual loss as a result of secondary retinal detachment, macular invasion, lens opacification or subluxation, and vitreous haemorrhage. Intolerable pain and an unsightly eye can eventually occur as a result of extraocular tumour exten sion, glaucoma or inflammation.
Several conditions must be met for an intraocular mel anoma to be left untreated. Firstly, there should be suf ficient doubt about the diagnosis of melanoma. Secondly, it should be possible to monitor the ocular status adequately, by means of regular ultrasonography and colour photography. Thirdly, the size of the tumour and the patient's life expectancy should indicate a low risk of metastatic disease in the event of the tumour being a mel anoma. Finally, observation of the tumour is easier to jus tify if any 'prophylactic' treatment would inevitably reduce vision because of proximity of the tumour to the optic disc or fovea.
INDICATIONS FOR CONSERVATIVE TREATMENT
A variety of methods for destroying uveal melanomas have been developed with the aim of conserving a useful eye, but these can be justified only if and when they do not increase the risk of metastatic disease as compared with enucleation.
With the exception of one small study,9 which as the authors acknowledge is biased because of poor matching of the tumours in the two treatment groups, the published data suggest that survival after radiotherapy is not signifi cantly different from that after enucleation.!O--13 These studies have been questioned because of their short follow-up times and because they were not performed in a randomised prospective manner.2 At present, a large multicentre investigation called the Collaborative Ocular Melanoma Study (COMS) is under way in the United
States and Canada and this may establish whether or not plaque radiotherapy reduces the chances of survival as compared with enucleation.14 Two investigations suggest that local surgical resection does not significantly increase the risk of metastatic disease as compared with enuclea tion, 1 5 , 16 but as with radiotherapy further long-term studies are required.
It is not the physical manipulation of the globe at the time of the primary treatment that is likely to alter the prognosis, but the presence of residual tumour. Tumour regrowth after radiotherapy is rare. After iodine plaque radiotherapy, for example, the recurrence rate was 7.8% in 64 patients with a mean follow-up of 65 months, 1 7 and after proton beam radiotherapy the recurrence rate was 1.9% in 1077 patients with a mean follow-up of 48 months.18 However, a large proportion of tumours remain bulky after radiotherapy, and histological examination of eyes which were not necessarily enucleated for tumour regrowth has shown viable tumour cells in nearly all cases, although the metastatic potential of these cells is not known.2 Visible residual tumour at the end of a local resec tion is very unusual when the operation is performed by a surgeon experienced in the technique, and the main prob lem is that of tumour recurrence from invisible micro scopic deposits located either in the sclera or retina within the surgical colobomal9 or, more commonly, in apparently normal choroid at the margins of the coloboma. The over all incidence of residual tumour after local resection is approximately 20%, but the problem has diminished as a result of ocular decompression during the local resection and prophylactic post-operative laser photocoagulation of the margins of the coloboma (B. E. Damato, J. Paul and W. S. Foulds, unpublished data). Furthermore, with proper follow-up, any recurrences are usually detected when they are still minute and treatable by photocoag ulation or plaque radiotherapy.
In the absence of any definite evidence that enucleation is better than conservative treatment in preventing meta static disease, enucleation is no longer the standard form of treatment for intraocular melanoma but is reserved for (1) patients who are unable or unwilling to receive regular and life-long ocular examination for tumour recurrence after treatment; (2) patients who cannot cope psychologi cally with the possibility of local tumour recurrence; (3) tumours which cannot be completely destroyed because of excessive involvement of the optic disc, ciliary body, angle or orbit; and (4) eyes which are unlikely to be con sidered useful by the patient after treatment. Whether or not the eye and vision are useful after treatment depends on the resulting visual acuity and field and the cosmetic appearance, which are judged according to the patient's own objectives. These are determined by factors such as age, gender, occupation, recreational activities, cultural background and vision in the fellow eye. When loss of central vision is inevitable, the importance of the temporal visual field should not be underestimated, especially if the patient wears spectacles.
CLINICAL METHODS

Pre-operative Management
Pre-operative ocular examination is aimed at diagnosing the tumour and defining the size and extent of the lesion and is based on biomicroscopy, indirect ophthalmoscopy, B-scan ultrasonography, and trans pupillary transillumina tion. Full clinical examination is directed at establishing the patient's fitness for general anaesthesia and excluding the presence of extraocular malignancy.
Informed consent is obtained after discussing in detail the various treatment options available together with their respective advantages and problems. Special care is taken to ensure that the patient understands the need for life-long monitoring after conservative treatment. To aid communi cation, each time I explain to a new patient about the tumour and its treatment, the conversation is recorded using a cassette tape-recorder, and the tape-recording given to the patient. Arrangements are made for appro priate counselling, taking due regard of what the patient wishes to know.
Plaque Radiotherapy
Plaque radiotherapy is currently the most popular form of conservative treatment for choroidal and ciliary body mel anomas because of its simplicity and convenience. The plaque is sutured to the sclera directly over the tumour after dis inserting any overlying extraocular muscles and localising the margins of the tumour by transpupillary transillumination. The implant usually remains in place for 5-7 days, depending on the age of the plaque, until the desired dose has been delivered. This is conventionally about 70-100 Gy at the tumour apex.
Initially, cobalt plaques were widely used, but the high incidence of radiational complications2°-22 has led to the adoption of less energetic isotopes such as ruthenium, iodine, and, recently, palladium.23 Ruthenium-l 06 plaques have been extensively used in Europe for tumours of up to 5 mm in thickness. 24 Iodine-125 plaques, which have been in use in North America since the mid-1980s, have now become the standard form of implant. 17,25 They have a half-life of approximately 60 days and emit gamm a-rays with sufficient energy to treat tumours with a thickness of more than 5 mm. The treatment of large tumours with iodine-125, however, is associated with a higher incidence of radiational complications. I? Accordingly, various methods are being developed to increase the radiosensitiv ity of uveal melanomas by hyperthermia, using ultra sound, microwaves or other means in the hope of reducing the dose of radiation.26--28 However, it has been suggested that ocular morbidity following radiotherapy is not necessarily due to the radiation but is caused by the pres ence of necrotic tumour tissue within the eye,29 in which case such developments may be only partially successful in preventing complications.
Charged Particle Radiotherapy
Charged particle radiotherapy of uveal melanomas is currently possible in about a dozen centres world-wide, although the number of cyclotron machines that can be used for this treatment is increasing. A highly collimated beam of protons30 or helium ions3 1 can be directed at the tumour with great precision. Because of a phenomenon known as the Bragg peak, the fall-off of the charged par ticles can be adjusted to within 1 mm, with the entry site receiving approximately 60-70% of the maximal dose. Prior to the treatment, four tantalum marker rings are sutured to the sclera so that the tumour can be localised radiographically. The dimensions of the tumour and the eye are measured and these data, as well as information regarding the marker locations, are computerised for treat ment planning (Fig. 1) . Between 50 and 70 Gy are delivered to the tumour in four fractions.
Local Resection
The surgical resection of small iris and ciliary body mel anomas has been performed for many years.32,33 Local resection of choroidal melanomas has been advocated only as a last resort, after unsuccessful radiotherapy in patients with poor vision in the fellow eye. 34 In 1972, how ever, Foulds started performing local resection of chor oidal melanomas as a primary procedure irrespective of the vision in the fellow eye35 and, in 1984, was joined by the author, who has performed some 250 such procedures to date. Interim results have been published 1 6, 3 6, 3 7 and, recently, other workers have adopted this type of operation.
15,38,39
The surgical techniques vary according to the size and location of the melanoma.36 Briefly, the tumour is local ised by transpupillary transillumination and the overlying extraocular muscles are disinserted. A lamellar scleral flap B. E. DAMATO is prepared, and the tumour is excised together with the deep scleral lamella and a surround of normal uveal tissue, if possible without damaging the subjacent retina. Access to the posterior tumour is facilitated by ocular decompres sion, which is achieved by pars plana vitrectomy. Haemor rhage is minimised by hypotensive anaesthesia, which reduces the systolic blood pressure to approximately 50 mmHg.40 After the tumour is removed, the scleral flap is sutured and the eye is reformed with gas, balanced salt solution or silicone. If a retinal defect is present, external plombage is also performed. After the operation the mar gins of the surgical coloboma are treated by laser photo coagulation to reduce the risk of local tumour recurrence and retinal detachment. Peyman had advocated an alter native method of performing local resection, in which the tumour is excised together with the retina and the full thickness of the adjacent sclera,41 but he has recently aban doned this in favour of the lamellar scleral dissection technique.
Endoresection
It is possible to excise small posterior tumours trans vitreally. The surface of the tumour and the surrounding retina are treated by photocoagulation, to eliminate any exudative retinal detachment and to create retino-chor oidal adhesion. A few weeks later, the tumour and rem nants of overlying retina are removed transvitreally using standard vitrectomy equipment. Complete removal of the tumour is followed by vitrectomy and photocoagulation of any residual pigmented tissue. At the end of the operation the eye is filled with balanced salt solution. Peyman has described a similar technique, but advocates preservation of the retina over the surgical coloboma and the use of silicone and panretinal ablation to prevent retinal detachment. 42
Photocoagulation Photocoagulation, using xenon,43,44 argon45 or krypton,46 is not often performed as a primary procedure and is usually reserved for adjunctive therapy after radiotherapy or local resection. For many years the standard technique was to apply brief, high-energy flashes of light, but in 1986 Foulds and Damato described a method using low-energy laser photocoagulation.46 After creating chorioretinal scars around the tumour and ablating the retina overlying the lesion, using an argon laser, the tumour is treated with long, low-energy krypton bums (e.g. 0.3 watts for 20 seconds). The tumour diminishes in thickness by only 0.5 mm after each treatment so that several sessions of photocoagulation are necessary to achieve a flat scar. Whilst the generally accepted view is that a flat grey scar (i.e, 'grey mouse') is an appropriate end-point, the author believes that it is important to end treatment only after the sclera has been exposed, either by creating several explo sions in the tumour remnants, using high-energy laser, or by endoresection. A novel technique has been described recently in which diode laser photocoagulation is applied, using intravenous indocyanine green injection to enhance the light absorption (Y. Shimoyma, et at., personal com munication, ARVO 1992). Experiments using an animal model have shown extensive tumour necrosis after such treatment, although whether or not the resulting inflam mation would be well tolerated by the eye has yet to be established.
Photodynamic Therapy
In addition to delivering thermal energy, light can be used to activate chemotherapeutic agents such as haemato porphyrin derivatives (HPD)47,48 and bacteriochlorin A,49 These are injected intravenously and accumulate within the tumour, which is then treated with a sub-thermal dose of light energy. At present, the use of HPD is limited by the risk of sunburn, which lasts for several weeks after treat ment, but in future such a problem may be avoided by tar geting HPD or indeed other agents at the tumour using heat-labile liposomes (M. H. Rahimy, B. Khoobehi and G, A. Peyman, personal communication, ARVO 1992).
Post-operative Management
After most forms of conservative treatment, patients are usually reviewed after approximately 1 month, then 6-monthly for about 5 years, then annually. Indirect oph thalmoscopy, biomicroscopy and colour photography are performed routinely in addition to B-scan ultrasonog raphy and transillumination. Systemic examination and special scans are performed only if symptoms suggest the presence of metastatic disease.
SELECTION BETWEEN DIFFERENT FORMS OF CONSERVATIVE TREATMENT
There is no single form of treatment which is ideal for all 391 intraocular melanomas, so that it is important to select the most suitable method according to (1) the size and location of the tumour, (2) secondary changes in the affected eye, (3) the general health and motivation of the patient, and (4) the equipment and skills available. When selecting between treatments on the basis of the published literature, only broad comparisons are possible because of the inconsistent ways in which different workers have categorised and evaluated their data.
Choroidal Tumours
For choroidal tumours with minimal or no involvement of the pars plicata, the primary determinants of treatment type are the tumour thickness and the proximity of the pos terior tumour margin to the optic disc and fovea (Fig. 2) .
Tumour Thickness Less Than 6 mm. If the tumour is less than 6 mm thick and does not extend to within 3-4 mm of the optic disc or fovea, the author's first choice is ruthe nium plaque radiotherapy, which is less difficult than local resection and less expensive than charged particle radio therapy. Iodine plaques, because of their relatively short half-life, are more expensive than ruthenium plaques and have an increased risk of causing radiational complica tions because of the deeper penetration of radiation, although comparative studies with ruthenium have not been performed. In 28 patients treated with ruthenium plaque radiotherapy, with a tumour thickness of less than 6 mm and a posterior tumour margin more than one disc diameter of the optic disc or fovea, 27 eyes retained vision of counting fingers or better after a minimum follow-up of 3 years, with 60% of all eyes having vision of 6/ 12 or bet ter (B, E, Damato, J. Paul, A. N. Harnett and W. S. Foulds, unpublished data). Other workers also report good results with such favourable tumours. [50] [51] [52] With tumours extending close to or involving the optic disc or fovea, the probability of visual loss from radi ational optic neuropathy or maculopathy after proton beam radiotherapy is about twice that of more anterior tumours, 53 The risk of visual loss after external beam radiotherapy is probably smaller than with plaques, despite the use of notched implants,54 With tumours having a tapering posterior edge, the visual result may be improved by placing the plaque eccentrically in relation to the tumour and treating the posterior edge by photocoag ulation (Fig. 3) . With posterior tumours, there is a higher risk of recurrent tumour both after external beam radio therapylS and after plaque radiotherapy. 54 This is because of difficulty in localising the tantalum marker rings pre cisely in relation to the posterior tumour margin and because the optic nerve may interfere with the correct positioning of the radioactive plaque. With small posterior tumours, it would be useful to compare the results of plaque radiotherapy with those of charged particle radiotherapy.
External beam radiotherapy of nasal juxtapapillary tumours may result in epiphora caused by damage to the lacrimal canaliculi.55,56 Such nasal and juxtapapillary tumours, if less than 4 mm in thickness, may be treated by photocoagulation, which can be followed by endoresec tion if the patient cannot attend for repeated treatment or if total tumour destruction cannot be achieved (Fig. 4) . Photocoagulation of macular and juxtapapillary tumours has a high risk of choroidal neovascularisation and vit reous haemorrhage, particularly if the major retinal vessels are occluded (Fig. 5) , so that external beam radio therapy is preferable for such cases.
Tumour Thickness More Than 5 mm. With tumours greater than 5 mm in thickness, ruthenium plaque radio therapy, photocoagulation and endoresection are not poss ible and the choice is between local resection, iodine plaque or external beam radiotherapy. After radiotherapy, the risks of complications such as radiation retinopathy, persistent retinal detachment and neovascular glaucoma are related to tumour thickness and diameter. For example, after proton beam radiotherapy the incidence of persistent retinal detachment is approxi mately 40% with tumours 4-10 mm in thickness and is almost 80% with tumours more than 10 mm in thick ness.57 Persistent retinal detachment after radiotherapy is untreatable and increases the risk of neovascular glau- Irradiation of large tumours with iodine plaques is also associated with significant morbidity. In 64 patients fol lowed up for a mean of 65 months 10.9% developed neo vascular glaucoma and 23.4% developed radiation retinopathy, with 17.2% of all eyes eventually requiring enucleation and 45% of all eyes retaining vision of 6/36 or better; however, this series included both small and large tumours as well as those extending close to the disc or fovea.I7 For tumours of equivalent size, external beam radiotherapy is more likely to cause neovascular glau coma whereas the probability of radiation retinopathy is greater with iodine plaque radiotherapy?9 In contrast to radiotherapy, increasing tumour bulk (up to a diameter of about 16 mm) and the presence of subret inal fluid facilitate local resection. The main complica tions after this procedure are residual tumour, as mentioned above, and retinal detachment. The overall incidence of rhegmatogenous retinal detachment after local resection is approximately 20%. This complication is most likely to occur (1) after irido-cyclo-choroidec tomy, which inevitably results in a large retinal dialysis, oidal melanoma extending close to the superior margin of the optic disc (a) before treatment, and (b) 6 years after ruthenium plaque radiotherapy and krypton laser photocoagulation to the posterior tumour margin. Despite the appearance of a few cot Ion wool spots and telangiectasia, a visual acuity of 6/6 was maintained until the patient's latest visit, almost 7 years after the radiotherapy.
(2) when the tumour has invaded the retina, and (3) with : small and posterior tumours, which are now treated by proton beam radiotherapy. The application of external plombage, internal tamponade and retinopexy at the time of the local resection seem to have reduced the incidence of retinal detachment. The results of local resection have been compared with those after cobalt plaque radio therapy,15 but the study was performed by workers with relatively little experience in local resection at the time, so the results are not representative of current techniques. There is scope for further studies comparing outcome in matched patients treated either by local resection, iodine plaque radiotherapy or charged particle radiotherapy.
Posterior tumour extension, to within one or two disc diameters of the disc or fovea, increases the probability of radiational optic neuropathy and maculopathy after plaque or external beam radiotherapy53 and also increases the likelihood of residual tumour and retinal damage after local resection. 36 Radiotherapy of tumours that extend anteriorly is asso ciated with a higher dose of radiation to ciliary body and lens so that there is an increased risk of neovascular glau coma, uveitis and cataract, particularly with bulky tumours.58 In addition, external beam radiotherapy of anterior tumours damages the superficial structures such as the eyelids, canaliculi and lacrimal gland to cause eye lid scarring, loss of lashes, keratopathy, epiphora and dry eye according to whether the tumour is nasal, superior or superotemporal respectively.55,56 In contrast to radio therapy, local resection does not affect these extraocular structures.
The quadrant of the eye affected by the tumour is rele vant not only with respect to the extraocular complications of external beam radiotherapy, as mentioned above, but also with regard to outcome after local resection. Vision after the excision of nasal choroidal tumours, for example, is significantly better than after the resection of temporal tumours, probably because nasal tumours do not extend as close to the fovea as temporal lesions (Fig. 6) . With nasal choroidal tumours not extending to within one disc dia meter of the disc or fovea, all 28 eyes were retained 1 year post-operatively, with more than 90% having vision of counting fingers or better and 57% having vision of 6/12 or better. With 56 temporal tumours not extending to within one disc diameter of the disc or fovea, 89% of eyes were retained at 1 year, with 82% having vision of count ing fingers or better and 25% having vision of 6/12 or bet ter (B. E. Damato, J. Paul and W. S. Foulds, unpublished data).
Ciliary Body Tumours
With tumours involving the ciliary body or angle, or both, B. E. DAMATO the results of treatment depend mostly on the extent of involvement of these structures (Fig. 7) . For small tumours involving a third of the ciliary body or less and not extending posterior to the ora serrata, iridocyclectomy is the treatment of choice because it is quick, straightfor ward and gives good results. With 33 such procedures the eye was retained in 32 patients, with 60% of all eyes having vision of 6/12 or better after a median follow-up of 43 months (Fig. 8) . With larger and more posterior tumours it is necessary to perform irido-cyclo-choroidec tomy, which is a more extensive procedure and inevitably causes a large retinal dialysis. After 75 such procedures only 67% of eyes were retained, with 50% of all eyes retaining vision of counting fingers or better and 12% having vision of 6/12 or better. Retinal detachment occurred in none of the patients treated by iridocyclec , tomy but in as many as 35% of patients after irido-cyclo choroidectomy. The complication rate was even higher when more than a third of the ciliary body was excised, which is why such extensive tumours are usually treated by enucleation (B. E. Damato, J. Paul and W. S. Foulds, unpublished data). With charged particle radiotherapy, 
Retinal Invasion
Retinal invasion was previously treated by retinectomy when local resection was performed, but this policy led to a high incidence of retinal detachment so that, currently, tumour within the retina is left in situ and treated post operatively by photocoagulation or plaque radiotherapy. If the tumour has perforated the retina, the risk of retinal detachment is increased not only after local resection but also after radiotherapy, when the tumour has regressed, so that cryotherapy and other prophylactic measures are indicated.
Extraocular Tumour Extension
Massive extraocular extension is treated by enucleation followed by a course of external beam orthovoltage radio therapy59 (e.g. 4500 cGy) or by exenteration. If only a small encapsulated episcleral nodule is present, however, its treatment depends on the management of the intra ocular tumour. When local resection is performed the epi scleral nodule is excised en bloc together with a surround of full-thickness sclera, and the defect is closed with a lamellar scleral graft taken from a healthy part of the same eye. If the intraocular tumour is being treated by plaque radiotherapy or e�ternal beam radiotherapy, then the epi scleral tumour nodule is included in the radiation field.
Secondary Ocular Changes
The more extensive the pre-operative exudative retinal detachment the greater is the incidence of persistent retc inal detachment after proton beam radiotherapy, increas ing from approximately 35% to 60% in patients with pre-operative detachment in two quadrants and three quadrants respectively.57 Conversely, the more extensive and exudative retinal detachment, the less chance there is of local resection being complicated by retinal damage.
Glaucoma may be caused by annular extension of the tumour around the angle, in which case conservative treat ment is contraindicated; but glaucoma could also be due to melanomacrophages or pre-existing open angle glaucoma. 60 Vitreous haemorrhage in the presence of a choroidal tumour suggests that the tumour has perforated the retina, so that preparations should be made for prophylactic measures against rhegmatogenous retinal detachment.
General Health
Systemic complications associated with the hypotensive anaesthesia have been few. In a series of 100 patients, 2 reported short-term memory loss lasting a few weeks and 2 developed temporary hemiparesis, with total recovery. 40 One patient in another series developed fatal per-operative pulmonary thrombo-embolism, which occurred before systemic hypotension had been achieved. The low inci dence of morbidity occurred because hypotensive anaes thesia was not performed in the presence of severe peripheral vascular disease, ischaemic heart disease or cerebrovascular disease. In elderly patients, mild hypoten sive anaesthesia is often sufficient to arrest haemorrhage, so that an age of more than 70 years is not necessarily a contraindication to local resection even when systemic hypotension is not possible. Patients who are not fit for local resection are treated by proton beam radiotherapy.
CONCLUSIONS
It is possible to conserve the eye in most patients when a uveal melanoma is less than about 17 mm in diameter and does not involve more than a third of the ciliary body or optic disc. Preservation of good vision can be expected in such patients if the tumour does not extend to within 3 mm of the optic disc or fovea. It is therefore no longer accept able for enucleation to be performed merely on the basis of any intuitive feelings of the surgeon, especially as such mutilating surgery does not seem to improve the chance of survival as compared with conservative treatment. The term 'informed consent' implies that the patient is aware of the advantages and disadvantages of all forms of treat ment. It is hoped that this overview will make it easier for the various therapeutic options and objectives to be con sidered when the patient with an intraocular melanoma is counselled.
